Cancer drug dasatinib tested to shrink hidden HIV reservoirs
NCT ID NCT05780073
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether a low dose of dasatinib, a cancer drug, is safe and can reduce the hidden HIV reservoir and inflammation in people with HIV who are already on effective antiretroviral therapy. Sixty participants took either dasatinib or a placebo daily for 24 weeks while continuing their regular HIV medications. The study measured safety, immune activation, and changes in the HIV reservoir.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dasatinib
- What this could lead to
- If it works, this could point toward a way to shrink the hidden HIV reservoir and reduce chronic inflammation in people already on antiretroviral therapy.
- What could go wrong
- This is a small, early-phase trial focused on safety and biological markers, not a cure. Dasatinib is a cancer drug with known side effects, and it may not meaningfully reduce the viral reservoir or improve health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION PRIMARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.